Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glenvastatin SCHEMBL1040745 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL29557142 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL1040744 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL9872411 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL49508 | 1.00 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9022892 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL10024037 | 1.00 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9527887 | 0.96 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9022328 | 0.94 | HMGCR (0.89) | HMGCR | |
| SCHEMBL9023237 | 0.92 | HMGCR (0.85) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713614-B2 | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2419399-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | C T RESOLVE SARL (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-20150272949-A1 | COMBINATION OF HMG-COA REDUCTASE INHIBITORS WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8673881-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120156216-A1 | Methods and Compositions for Treatment of Tumor Metastasis | OH YOUNGMAN (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | SCHWARTZ C ERIC | 2011-10-06 | — | — | US | disclosed |
| EP-2363130-A1 | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | Nycomed GmbH (DE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2359826-A1 | Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases | Nycomed GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2011-04-28 | — | — | US | disclosed |
| US-20100069392-A1 | Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease | NYCOMED GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20090069623-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF RADIATION-INDUCED FIBROSIS | VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | AMPLA PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20050239871-A1 | Statins for the treatment of ocular hypertension and glaucoma | ALCON, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | ALOX15B, ALOX5, ALOX15 | HMGCR 32/4885 |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | HMGCR 137/4885 |
| US-20090069623-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF RADIATION-INDUCED FIBROSIS | FN1, HDGF, RHOA | HMGCR 1361/4885 |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | ALOX5, ALOX15B, ALOX12 | HMGCR 69/4885 |
| US-20080140450-A1 | Treatment of metabolic syndrome with norfluoxetine | ADRB3, FFAR3, SLC6A4 | HMGCR 22/4885 |
| US-20050239871-A1 | Statins for the treatment of ocular hypertension and glaucoma | HMGCR, HMGB2, GRHPR | HMGCR 1/4885 |
| US-20120156216-A1 | Methods and Compositions for Treatment of Tumor Metastasis | RHOA, HMGCR, HGF | HMGCR 2/4885 |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | HMGCR 137/4885 |
| US-20150272949-A1 | COMBINATION OF HMG-COA REDUCTASE INHIBITORS WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES | HMGCR, HMGB3, PDE4A | HMGCR 1/4885 |
| US-20100069392-A1 | Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease | HMGCR, HMGB3, PDE4A | HMGCR 1/4885 |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | HMGCR, HMGB2, GRHPR | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.